728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Golden Meditech Announces FY2017/2018 Interim Results

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

Qinghe Hospital Achieves Revenue Contribution, Significant Growth in Healthcare Services Business
Strategic Roadmap in the Advanced Medical Fields to Diversify the Group’s Business and Revenue Stream

HONG KONG, Nov. 30, 2017 /PRNewswire/ — Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) (“Golden Meditech” or the “Company”, together with its subsidiaries, the “Group”), a leading integrated healthcare enterprise in China, announces today its interim results for the six months ended 30 September 2017 (the “Reporting Period”).

For the Six Months Ended 30 September

2017

(HK$’000)

2016

(HK$’000)

Change

(%)

Continuing Operations

Revenue

 

117,069

 

121,672

 

(3.8)

Healthcare services segment revenue

50,028

31,885

56.9

   Hospital management services income

47,865

29,901

60.1

   Medical insurance administration services income

2,163

1,984

9.0

Medical devices segment revenue

65,189

87,615

(25.6)

Strategic investments revenue

1,852

2,172

(14.7)

Gross profit

50,358

61,784

(18.5)

Loss from operations

(100,156)

(162,014)

(38.2)

Finance costs

(199,807)

(171,789)

16.3

(Loss)/profit attributable to the Company’s equity shareholders

(63,092)

(394,437)

(84.0)

    –                Continuing operations

(287,444)

(317,154)

(9.4)

    –                Discontinuing operation 

224,352

(77,283)

N/M

Basic (loss)/earnings per share (in HK cents)

(2.13)

(13.30)

(84.0)

    –                Continuing operations

(9.69)

(10.69)

(9.4)

    –                Discontinuing operation

7.56

(2.61)

N/M

During the Reporting Period, the Group’s total revenue from continuing operations was HK$117,069,000, decreased by 3.8% year-on-year. The decrease has slowed down as compared to the corresponding period last year, mainly attributable to further optmisation on the Group’s revenue mix. Healthcare services revenue as a % of total revenue from continuing operations increased to 42.7% from 26.2% in the corresponding period last year.

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *